Norwegian biotech concludes 'strategic' review with a reverse merger

Max Gelman

Senior Editor

A little Norwegian biotech announced the end of its journey Thursday in a reverse merger, roughly three months after announcing it would essentially sell itself …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Norwegian biotech concludes 'strategic' review with a reverse merger

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

How AI can address ongoing challenges in the life sciences industry

Nor­we­gian biotech con­cludes 's­trate­gic' re­view with a re­verse merg­er

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Norwegian biotech concludes 'strategic' review with a reverse merger